Senores Pharmaceuticals Ltd
SENORESSenores Pharmaceuticals Ltd is strength at full price. The numbers are improving — and a P/E at the 86th percentile of its own range says the market knows.
The sharpest disagreement: profits are rising, but only −5% of the last 3 years' profit arrived as operating cash — the gap between the P&L and the bank account is the thing to watch.
The price is in a confirmed uptrend (60 weeks in) while the P/E sits at the 86th percentile of its own 2-year range. Underneath, the last four quarters read improving — profit +42.9% year on year, and −5% of the last 3 years' profit arrived as cash. What settles it: whether the cash starts following the profit.
Price story Before the numbers, the tape. A stock price moves through four repeating seasons: a flat base (stage 1), an advance (2), a top (3), a decline (4). Where the price sits in that cycle frames everything below.
Senores Pharmaceuticals Ltd trades at ₹1,467, in a confirmed uptrend and 60 weeks into that stage. That is +32.6% against its own 200-day average. It sits at 94% of a 52-week range of ₹727 to ₹1,513. On relative strength it has been ahead of the NIFTY 500 on a trailing-13-week view for 29 straight weeks.
Today the stock is in a confirmed uptrend — week 60 of stage 2, confirmed. At ₹1,467 it trades +32.6% versus its 200-day average and sits at 94% of its 52-week range (₹727–₹1,513).
Against the market, two honest reads. Cumulative: over the last 1.7 years the stock moved +156% while the NIFTY 500 moved +3% — ahead of the index over the full window. Recent form: on a trailing-13-week view the stock has been ahead for 29 straight weeks — the ribbon below is that same metric, week by week.
What would end the trend, mechanically: two Friday closes in a row below the 200-day line. That is the exit rule — no debates.
Story check
Senores Pharmaceuticals Ltd's story is not scored yet against the markers our research file set on 22 August 2026. Where it sits in its own cycle: MID_EXPANSION_WITH_NEAR_PEAK_PE. Our fortnightly research layers last read it on 22 August 2026.
Our read, 22 August 2026. Senores is expanding its regulated-market product platform, but a 55.1x trailing PE at the observed peak and unresolved cash and dilution leads require a valuation-risk-first stance.
From the numbers. The current weekly PE/PB snapshot places the stock in BREAKOUT_FROM_COMPRESSION with an EMERGING_OPPORTUNITY matrix tag, improving QoQ momentum, and FII_BUYING. The deterministic normalization takes precedence for…
From the price. Price stage 2, week 60 — above its 200-day line, relative strength falling.
From the research. Senores is expanding its regulated-market product platform, but a 55.1x trailing PE at the observed peak and unresolved cash and dilution leads require a valuation-risk-first stance.
🚨 Where they disagree. The current weekly PE/PB snapshot places the stock in BREAKOUT_FROM_COMPRESSION with an EMERGING_OPPORTUNITY matrix tag, improving QoQ momentum, and FII_BUYING. The deterministic normalization takes precedence for valuation framing: PE is 55.1x, at the observed peak, with an 88th-percentile reading, while normalized PE is 70.9x. Earnings are expanding, but the margin-history verdict is NA_SHORT_MARGIN_HISTORY because only about 2.8 years of OPM history are available. This is therefore a mid-expansion operating read with rich near-peak valuation, not a cheap or trough read.
What is proven. Senores is expanding its regulated-market product platform, but a 55.1x trailing PE at the observed peak and unresolved cash and dilution leads require a valuation-risk-first stance.
What is not proven yet. Two consecutive quarters of operating cash conversion above 70% of PAT, no further increase in implied share count, and sustained FY27 delivery within the 30-40% revenue and 50-60% PAT guidance ranges would reduce the valuation-trap concern; an official adverse US FDA action or PAT growth below 20% YoY would worsen it.
🚨 What would change our mind. Two consecutive quarters of operating cash conversion above 70% of PAT, no further increase in implied share count, and sustained FY27 delivery within the 30-40% revenue and 50-60% PAT guidance ranges would reduce the valuation-trap concern; an official adverse US FDA action or PAT growth below 20% YoY would worsen it.
🚨 Layer 1 read, 22 August 2026 — DROP. The launch pipeline is converting — but the price already assumes it, and cash is stuck in customer invoices. The engine is real and improving: revenue reached Rs 180 crore in the June quarter, up 30.4%, with operating profit of Rs 54 crore — the highest ever — even though headline profit slipped, because roughly Rs 15 crore of one-off currency gain dropped out. The fuel for the next two years is nameable: about 58 approved product filings, 23 already selling and 35 ready to launch, with management guiding 30-40% revenue growth. What holds this at second-tier is that the shares now trade at their most expensive level ever after a 117% year, the company has revised or pivoted away from five of its eight stated targets, and customer invoices have swollen from 114 to 187 days of sales — money earned…
What would change Layer 1’s mind. Sharpening the timeline own test: what flips this to a drop is receivable days rising ABOVE 187 in the FY27 audited accounts while payable days fall back below 275 — that combination would mean the cash squeeze is no longer being financed by suppliers and has to be funded with real money, at a company already at Rs 342 crore of borrowings. Conversely, what lifts it to first tier is two consecutive quarters of operating cash flow above 70% of profit — the company own milestone M5 — together with…
The test written in advance. Near-Peak Valuation and Margin-Normalization Trap — Near-Peak Valuation and Margin-Normalization Trap Trailing PE, normalized PE, quarterly PAT growth, operating cash flow, and implied share count. by the next result.
The test written in advance. Regulatory Compliance and US FDA Inspection Risk Across Production Sites — Regulatory Compliance and US FDA Inspection Risk Across Production Sites US FDA inspection notices, EIRs, warning letters, or import-alert disclosures. by the next result.
What the company does. Approved ANDAs rose from 12 in December 2024 to about 58 in June 2026; 23 were commercialized and 35 were prepared for launch. The latest quarter delivered revenue of Rs 180 crore, 30.4% YoY growth, a 30% OPM, and PAT of Rs 30 crore, 42.9% YoY growth. The normalized engine treats the stock as rich with a near-peak PE and insufficient margin history for a through-cycle margin verdict; the chief test is whether earnings convert into cash without further dilution.
| Dial | Now | Was | Why it matters | Watch line |
|---|---|---|---|---|
| Regulated Market ANDA Commercialisation… | in play | — | About 58 approved ANDAs, 23 commercialized and 35 prepared for launch provide an identified commercial pipeline. | Launch timing slips materially, products fail to convert into sales, or pricing pressure offsets new-product contribution. |
| Aptyp Oral Solid Manufacturing Ramp | in play | — | Aptyp commercialized six products, produced about 30 million units, and operated at 80-90% utilization in Q1 FY27. | Utilization rises without commercial revenue, qualification is delayed, or compliance observations impair product transfer. |
| Emerging Markets Realization and PIC/S… | in play | — | Emerging-market revenue grew 30% YoY in Q1 FY27, while PIC/S timing could expand filing access. | PIC/S approval is delayed, registration costs remain elevated, or currency and product mix prevent margin recovery. |
| Multi-Channel US Commercial Front End | in play | — | Management described four US commercial routes spanning own-label sales, government business, B2B out-licensing, and CDMO/CMO… | Distribution and government-business costs increase without product or contract conversion. |
🚨 What the surface reading misses. The surface reading is: FY26 revenue grew 59.0% YoY. The research reads it further: Revenue scale supports the operating platform but does not establish cash-funded growth.
🚨 What the surface reading misses. The surface reading is: FY26 PAT increased 110.3% YoY. The research reads it further: PAT growth is substantial, but the cash-debt dig prevents equating reported profit with owner cash flow.
Lever 12 · New product launch — BUILDING. About 58 approved ANDAs, 23 commercialized and 35 prepared for launch provide an identified commercial pipeline. What proves it keeps working: Regulated Market ANDA Commercialisation Pipeline. It stops working if Launch timing slips materially, products fail to convert into sales, or pricing pressure offsets new-product contribution.
Lever 2 · Value-added mix — BUILDING. Emerging-market revenue grew 30% YoY in Q1 FY27, while PIC/S timing could expand filing access. What proves it keeps working: Emerging Markets Realization and PIC/S Access. It stops working if PIC/S approval is delayed, registration costs remain elevated, or currency and product mix prevent margin recovery.
Sources: our stock research file (22 August 2026) · quarterly results through Jun 26 · the company’s own earnings calls. The story check is re-scored every results season; the record below never changes.
| Section | Where it is now | Vs a year ago | The one thing to watch next | Read |
|---|---|---|---|---|
| Margin | 19% | — | Emerging Markets Realization and PIC/S Access |
Revenue Revenue is the top line: everything the company billed its customers in the period.
Senores Pharmaceuticals Ltd reported ₹180 Cr of revenue in the Jun 26 quarter, +30.4% year on year. That is the 7th straight quarter of year-on-year growth. Over 4 years it has compounded at 159.3% a year. The last full year, FY26, came in at ₹633 Cr. The last four reported quarters add to ₹688 Cr.
FY26 revenue came in at ₹633 Cr (+59.0% on the year), capping 4 years at 159.3% compound. The latest quarter (Jun 26) printed ₹180 Cr, +30.4% year on year — the 7th consecutive quarter of year-over-year growth.
Pace check: the last four quarters averaged +52.6% growth against the decade's 159.3% — the current year is running slower than its own long-run rate.
FY26-Q4. revenue ₹175 Cr and profit ₹37 Cr as reported.
FY27-Q1. revenue ₹180 Cr and profit ₹30 Cr as reported.
Why-sources: our stock research file (22 August 2026) and the company’s own results for those quarters.
Operating margin Operating margin is what is left of every ₹100 of sales after running the business, before interest and tax. It is the cleanest read on pricing power and cost control.
Senores Pharmaceuticals Ltd's operating margin is 30.0% in the Jun 26 quarter, +5.0 percentage points against the same quarter a year ago. Across 5 fiscal years the operating margin has ranged 14.0% to 36.0%. The current quarter sits inside that band.
Why this happened. Management reported Q1 FY27 emerging-market revenue growth of 30% YoY and approximately Rs 18 crore of operating cash. It retained an 18-20% full-year EBITDA-margin framework after a 14% Q1 margin, attributing the quarter to seasonality, product mix, and registration costs.
The latest quarter's operating margin is 30.0%, +5.0 pp against the same quarter a year ago. Across 5 fiscal years the operating margin has ranged 14.0%–36.0%.
Why the margin moved: operating margin went +5.1 pp year on year while gross margin went +8.0 pp — the gain came mostly from the gross line: input costs and pricing.
FY26-Q4. revenue ₹175 Cr and profit ₹37 Cr as reported.
FY27-Q1. revenue ₹180 Cr and profit ₹30 Cr as reported.
Why-sources: our stock research file (22 August 2026) and the company’s own results for those quarters.
Net profit Net profit is what survives every cost, interest and tax — the number EPS, dividends and book value all grow from.
Senores Pharmaceuticals Ltd earned ₹30.0 Cr of net profit in the Jun 26 quarter, +42.9% year on year. It is the 7th consecutive quarter of growth. Full-year FY26 profit was ₹122 Cr. The 4-year compound rate is 232.3%. That is 16.7% of the quarter's revenue. The same quarter a year earlier earned ₹21.0 Cr.
Jun 26 profit was ₹30.0 Cr, +42.9% year on year — the 7th consecutive quarter of growth. On the full year, FY26 printed ₹122 Cr (+110.3%), and the 4-year compound rate is 232.3%.
Why profit moved: revenue contributed +30.4% and the margin +5.0 pp — the quarter was margin-led: most of the profit growth came from keeping more of each sale.
Pace comparison, last four quarters: profit +97.9% vs revenue +52.6%. Profit is growing faster than sales — fixed costs are being spread over a bigger base, and each extra rupee of revenue drops more to the bottom line.
FY26-Q4. revenue ₹175 Cr and profit ₹37 Cr as reported.
FY27-Q1. revenue ₹180 Cr and profit ₹30 Cr as reported.
Why-sources: our stock research file (22 August 2026) and the company’s own results for those quarters.
Cash flow — the router The P&L says what was earned; the cash-flow statement says what actually arrived. Operating cash flow (CFO) against profit is the cleanest lie detector in the accounts.
Over the last 3 fiscal years −5% of Senores Pharmaceuticals Ltd's reported profit arrived as operating cash — a gap worth watching. In FY26 that was ₹62.0 Cr of operating cash against ₹122 Cr of profit. After ₹330 Cr of capital spending, ₹−268 Cr was left as free cash.
FY26: operating cash of ₹62.0 Cr against reported profit of ₹122 Cr, leaving free cash of ₹−268 Cr after ₹330 Cr of capital spending. Across the last 3 fiscal years the conversion rate is −5% of profit.
Cash-flow readings here are annual — that is the resolution our series carries, so this section moves once a year.
🚨 Why conversion sits at −5%: the cash cycle tightened 341 days between FY22 and FY26 — cash that used to wait in the cycle now reaches the bank sooner. Less than 70% of profit arriving as cash is the thing to watch on this page.
Router verdict: the bigger cash user is investment — capital spending ran 13.3× depreciation over three years, so the next section's job is to check what that build-out is buying.
Where the cash goes Working capital is the cash tied up between paying suppliers and getting paid: debtor days (customers owe), inventory days (stock waits), and the cash conversion cycle (the whole loop, in days of sales).
Senores Pharmaceuticals Ltd's cash conversion cycle runs −24 days in FY26, down from 317 days in FY22. Capital spending ran ₹769 Cr over the last 3 years. At FY26 sales of ₹633 Cr each day of that cycle holds about ₹1.7 Cr, so roughly ₹−42.0 Cr sits inside the business at any moment.
FY26: debtors at 187 days, inventory at 130 days — roughly 4.3 months of stock waiting to sell; that is where the cash sits while it waits — for a full cycle of −24 days, tighter than FY22's 317.
The full loop: cash goes out to suppliers and production on day 0; stock waits 130 days to sell; customers pay about 187 days after that; and suppliers themselves are paid at 340 days — netting out to the −24-day cycle.
In money terms: at FY26 sales of ₹633 Cr, each day of the cycle holds about ₹1.7 Cr — so the −24-day loop keeps roughly ₹−42.0 Cr sitting inside the business at any moment.
On the investment side: capital spending of ₹769 Cr over the last 3 fiscal years against ₹58.0 Cr of depreciation — the company is building well ahead of wear-and-tear. Capital work-in-progress stands at ₹17.0 Cr (FY26) — capacity paid for but not yet earning.
The synthesis: the cash is going into capacity, not disappearing into the cycle — the question becomes whether the new capacity earns.
Return on capital Return on capital employed (ROCE) is the profit the whole business earns on all the money in it — equity and debt together. It is the single best test of whether growth creates value or just size.
Senores Pharmaceuticals Ltd earns a ROCE of 15% in FY26. That is up from a trough of 11% in FY25. A return-on-invested-capital spread against the cost of capital is not computable from what is held here. The wiring behind it is 19.3% net margin on 0.39× asset turns.
FY26 ROCE is 15%, recovered from a FY25 trough of 11% — the full ladder below shows the fall and the climb, undoctored.
Why the return is what it is — the wiring (FY26): 19.3% net margin × 0.39× asset turns × 1.72× balance-sheet leverage ≈ 12.9% on equity. Margin is doing the heavy lifting; leverage is a meaningful part of the equation.
The quarterly return curves and the return-on-invested-capital overlay, which only the second data source carries, are not drawn on this page: its two data sources disagree by up to 13% on reported income across 10 comparable periods. A figure two sources cannot agree on is not drawn — the gap is a decision, not missing data.
Debt Debt-to-equity says how much of the business is funded by borrowings; interest cover says how many times operating profit pays the interest bill. Low and high, respectively, is the safe corner.
Senores Pharmaceuticals Ltd carries ₹342 Cr of borrowings against ₹934 Cr of equity in FY26, a debt-to-equity of 0.37. Operating profit covers the interest bill 7×. Over 4 years borrowings went from ₹15.0 Cr to ₹342 Cr. Capital spending ran ₹769 Cr across the last 3 of those years.
FY26: borrowings of ₹342 Cr against equity of ₹934 Cr — a debt-to-equity of 0.37. Operating profit covers the interest bill 7×. Over 4 years borrowings went from ₹15.0 Cr to ₹342 Cr while capital spending ran ₹769 Cr in just the last 3 — part of the build-out is riding on borrowed money.
The total-debt and debt-to-equity series, which only the second data source carries, are not drawn on this page: its two data sources disagree by up to 13% on reported income across 10 comparable periods. A figure two sources cannot agree on is not drawn — the gap is a decision, not missing data.
Ownership Who owns the stock, quarter by quarter: promoters (the controlling owners), foreign and domestic institutions, and the public. Steady accumulation by people close to the numbers is a signal; a quiet register is also an answer.
Foreign institutions added 2.4 points of Senores Pharmaceuticals Ltd over 6 quarters, the biggest move on the register. That takes foreign institutions to 6.6% of the company. Domestic institutions moved −2.0 points over the same window, to 9.8%. The register is read on the four disclosed classes only; nothing is inferred between filings.
The register over the last two years — Foreign institutions: +2.4 points over 6 quarters to 6.6%; Domestic institutions: −2.0 points over 6 quarters to 9.8%; Promoters: +0.0 points over 6 quarters to 45.8%.
Why the register moved: rotation — foreign institutions +2.4 points against domestic institutions −2.0 points over 6 quarters, with promoters holding steady — one class of institutions handing the register to the other, not a verdict change by the people closest to the numbers.
Safety line The Z-score estimates how far a company sits from balance-sheet distress — above roughly 3 is safe, below roughly 1.8 is the danger zone. It was built for manufacturers, so it is not applied to banks and lenders.
Senores Pharmaceuticals Ltd: the Z-score is not available for this stock, so we say so rather than invent one. It is a distance-to-distress estimate from the balance sheet, not a forecast of failure. The debt, cash-flow and return sections above carry the balance-sheet evidence this page does hold, and each of them states its own reporting date.
The safety line in one sentence: the Z-score is not available for this stock, so we say so rather than invent one.
Valuation P/E is the price of ₹1 of annual profit: how many rupees the market pays for each rupee the company earns in a year.
Senores Pharmaceuticals Ltd trades at 53.5× P/E, at the pricey end of its own range (86th percentile). Its long-run median P/E is 44.2×, measured across 1.7 years of weekly readings. This places the multiple against the stock’s own record, and says nothing about what the business is worth.
Today's P/E of 53.5× is at the pricey end of its own range (86th percentile), against a long-run median of 44.2× measured over 1.7 years of weekly readings. This is a comparison against the stock's own history — not a claim about what it is worth.
Why the multiple sits where it does: over the past year annual EPS moved +96.9% against a +112.7% price move — the price outran earnings, pushing the multiple UP its own range.
Put together: the multiple is full against its own past, so the story rests on the earnings line underneath it, not the multiple.
The PEG ratio and its quarterly curve, which only the second data source carries, are not drawn on this page: its two data sources disagree by up to 13% on reported income across 10 comparable periods. A figure two sources cannot agree on is not drawn — the gap is a decision, not missing data.
What the price assumes This reading works the multiple backwards. It asks one question: what yearly rate of profit growth is a buyer at the market price already paying for? The number is the growth rate that makes eleven years of profit — six years growing, then five fading — add up to that day's market price, once each year is discounted at 11% a year.
Solved at its 26 August 2026 price, Senores Pharmaceuticals Ltd was paying for profit growth of about 28.0% a year. Profit itself has compounded 232.3% a year over the past 4 years. Today the market pays 53.5× P/E, the 86th percentile of its own 2-year range.
What the two numbers say together. The multiple is full against its own past, and the growth the price is paying for is below what this company has actually delivered.
How to hold this number: it is a reading of one day's price, taken on 26 August 2026, not a running figure — every other number on this page, the multiple included, is read off the live quote as of 11 September 2026. A higher price is paying for more growth and a lower price for less, so it moves whenever the price does, and this page does not restate it between measurements.
Stage: No read Every business sits somewhere on a fundamental arc, and this page names the spot before anything else. The last twelve quarters of revenue, profit and EPS growth — plus the return the business earns on its capital — are read as curves: Deteriorating (the curves are falling), Turning around (a trough has just formed and the last few quarters lift off it), Improving (the climb off the trough is sustained), Consistent (steadily positive with healthy returns), Topping out (still high but decelerating from the peak). When the curves genuinely disagree the read is Mixed; too little history is No read. CAGR (compound annual growth rate) is the smooth yearly pace that turns the starting value into the latest one — the fairest way to compare growth across different time spans. Read the columns together: if the 1-year number towers over the 10-year, recent growth is running hotter than the long-run trend. A dash means that window is not held, or the base year was a loss (where a growth rate is not meaningful).
Senores Pharmaceuticals Ltd reads as no read on its fundamental arc. Under eight usable quarters on the growth trio — not enough history for an honest trajectory read. The read is built from 7 quarters across 1 curve, on partial evidence.
Why it matters: with too little history, an honest page says so instead of guessing a trajectory.
One or more growth curves carry a base-effect spike — a large year-on-year move off a near-zero or loss-making comparable quarter. Those spikes are capped before the classifier reads the trajectory, and shown pinned on the chart, so a single distorted quarter does not drive the stage call.
Return readings here are annual, not quarterly — read as level and direction only; they can confirm the growth curves but never drive the stage on their own.
Fewer than eight usable quarters on the growth curves — this page will not guess a trajectory from a stub of history.
| 1yr | 3yr | 5yr | 10yr | |
|---|---|---|---|---|
| Revenue | +59.0% | +162.5% | — | — |
| Profit | +110.3% | +148.0% | — | — |
| EPS | +96.9% | +42.9% | — | — |
| Share price | +112.7% | — | — | — |
4-Factor Sector Score
71.5/100 — rank 1 of 14 in Pharma - API · 75% evidence confidence
Senores Pharmaceuticals Ltd scores 71.5 out of 100 against the 14 companies it is compared with in Pharma - API, ranking 1. Confirmed research leader: earnings, capital efficiency and relative strength agree. Move to management, catalyst and risk diligence.
The four contributions add to the total exactly: 32.4 + 17 + 9.2 + 12.9 = 71.5. This is the SAME number shown on the sector comparison — it is computed once, for the whole peer set, and read here.
What would change it: The read weakens if profit growth turns negative or margin improvement reverses while sector-relative strength deteriorates.
Said versus delivered
What Senores Pharmaceuticals Ltd's management promised, set against what actually arrived — 4 tracked promises on the record. Read straight from the company’s own earnings calls. A promise that slipped stays on this page after it is met.
Branded Generics Outlook Not Reconciled · 27 July 2026. In Jan 2026, management projected INR80-plus crores for branded generics in the next year, following the INR100-odd-crore plan stated in Nov 2025. In Jul 2026, management stated a 50-60-crore full-year target for the India domestic business; although it attributed the moderation to a profitability-first strategy, it did not reconcile this materially lower target or clarify whether the domestic target uses the same segment perimeter.
🚨 Apna Pharma FY27 Revenue Guidance Materially Downgraded · 14 May 2026. In the Jan 2026 call, management guided INR120-150 crores of Apna Pharma revenue for FY27, representing a key pillar of the consolidated growth outlook. By the May 2026 call, the same guidance had been revised down to INR80-100 crores per Q&A responses, a reduction of approximately 33-47% from the prior range, with no explanation provided for the downgrade despite Apna Pharma commercial shipments having already commenced.
India Branded Generic FY27 Revenue Target Significantly Reduced · 14 May 2026. Management projected approximately INR100 crores in India branded generic revenue for FY27 in the Nov 2025 call and reiterated at INR80-plus crores in the Jan 2026 call. The May 2026 call revised this down to INR60-70 crores for the same FY27 period, a 30-40% reduction from the original projection, with no explanation provided for the lower target despite management citing continued business momentum in the segment.
US Commercial Entity Changed from Zoraya to Soraia Without Explanation · 14 May 2026. The Nov 2025 and Jan 2026 calls both highlighted Zoraya Pharmaceuticals as Senores' US marketing and distribution vehicle, described as a 51% JV formed with a partner holding several decades of US market experience. The May 2026 call makes no mention of Zoraya, instead introducing Soraia Pharmaceuticals - acquired as a step-down subsidiary also in Q3 FY26 - serving an essentially identical US marketing and distribution function, leaving investors without any explanation of what happened to the Zoraya JV or whether the ownership and partnership structure changed.
Every quote above is taken word for word from the company’s own earnings calls.
| Company | Score | Price stage | Growth & earnings/35 | Capital efficiency/25 | Valuation/20 | Relative strength/20 |
|---|---|---|---|---|---|---|
| 1Senores Pharmaceuticals Ltdthis pageSENORES | 71.5/100Favorable setup75% evidence | LEADER | 32.4/35 Revenue 50.9% · PAT 92.7% · OPM change 5 pp 95% evidence | 17.0/25 ROCE 15.1% · OPM 30% 76% evidence | 9.2/20 P/E 53.5× · PEG — 15% evidence | 12.9/20 RS sector 13.2% · RS bench 51.9% · 1Y 104%12 of 12 weeks ahead 100% evidence |
| Exact sum: 32.4 + 17 + 9.2 + 12.9 = 71.5 · Decision use: Confirmed research leader: earnings, capital efficiency and relative strength agree. Move to management, catalyst and risk diligence. | ||||||
| 2Wanbury LtdWANBURY | 63.5/100Mixed-positive evidence81% evidence | ASLEEP | 19.9/35 Revenue 3.6% · PAT 30% · OPM change -5.2 pp 95% evidence | 18.6/25 ROCE 30.7% · OPM 9.8% 95% evidence | 14.3/20 P/E 14.1× · PEG — 50% evidence | 10.7/20 RS sector 5.3% · RS bench -4.7% · 1Y -14.5%5 of 11 weeks ahead 70% evidence |
| Exact sum: 19.9 + 18.6 + 14.3 + 10.7 = 63.5 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 3Innova Captab LtdINNOVACAP | 57.7/100Mixed-positive evidence100% evidence | LEADER | 24.8/35 Revenue 34.4% · PAT 18.5% · OPM change 1 pp 100% evidence | 13.2/25 ROCE 15% · OPM 16% 100% evidence | 5.9/20 P/E 42.6× · PEG 4.06 100% evidence | 13.8/20 RS sector 4.3% · RS bench 41.6% · 1Y 26.2%11 of 12 weeks ahead 100% evidence |
| Exact sum: 24.8 + 13.2 + 5.9 + 13.8 = 57.7 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 4Ind-Swift Laboratories LtdINDSWFTLAB | 55.2/100Mixed-positive evidence87% evidence | LEADER | 23.1/35 Revenue 53.9% · PAT -74.3% · OPM change 14.6 pp 95% evidence | 6.0/25 ROCE 4.7% · OPM 17% 95% evidence | 6.1/20 P/E 51.5× · PEG — 50% evidence | 20.0/20 RS sector 88.3% · RS bench 147.7% · 1Y 277.6%12 of 12 weeks ahead 100% evidence |
| Exact sum: 23.1 + 6 + 6.1 + 20 = 55.2 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 5Anuh Pharma LtdANUHPHR | 53.1/100Mixed-positive evidence87% evidence | TURNING | 16.5/35 Revenue 9.7% · PAT -2.2% · OPM change 2 pp 95% evidence | 12.9/25 ROCE 14.9% · OPM 8% 95% evidence | 12.9/20 P/E 21.5× · PEG — 50% evidence | 10.8/20 RS sector -13% · RS bench 20.3% · 1Y 11.8%3 of 12 weeks ahead 100% evidence |
| Exact sum: 16.5 + 12.9 + 12.9 + 10.8 = 53.1 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 6Jagsonpal Pharmaceuticals LtdJAGSNPHARM | 51.1/100Mixed-positive evidence87% evidence | BREAKING OUT | 15.7/35 Revenue 3.2% · PAT -24.6% · OPM change 2 pp 95% evidence | 18.9/25 ROCE 22.7% · OPM 21% 95% evidence | 11.1/20 P/E 32.7× · PEG — 50% evidence | 5.4/20 RS sector -16.6% · RS bench 14.2% · 1Y -3.1%11 of 12 weeks ahead 100% evidence |
| Exact sum: 15.7 + 18.9 + 11.1 + 5.4 = 51.1 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 7Gujarat Themis Biosyn LtdGUJTHEM | 48.2/100Mixed-negative evidence93% evidence | TURNING | 20.1/35 Revenue 16.1% · PAT 6.7% · OPM change 9 pp 100% evidence | 15.6/25 ROCE 14.8% · OPM 48% 100% evidence | 6.9/20 P/E 113× · PEG 2.55 65% evidence | 5.6/20 RS sector -16.4% · RS bench 15% · 1Y 10.3%5 of 12 weeks ahead 100% evidence |
| Exact sum: 20.1 + 15.6 + 6.9 + 5.6 = 48.2 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 8Aarti Drugs LtdAARTIDRUGS | 46.8/100Mixed-negative evidence100% evidence | BREAKING OUT | 17.7/35 Revenue 10.5% · PAT 1.1% · OPM change 1 pp 100% evidence | 12.0/25 ROCE 12% · OPM 14% 100% evidence | 11.7/20 P/E 20.3× · PEG 2.4 100% evidence | 5.4/20 RS sector -22.6% · RS bench 6.9% · 1Y -9.1%9 of 12 weeks ahead 100% evidence |
| Exact sum: 17.7 + 12 + 11.7 + 5.4 = 46.8 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 9Fermenta Biotech LtdFERMENTA | 45.6/100Mixed-negative evidence74% evidence | BREAKING OUT | 5.0/35 Revenue -3.1% · PAT -44% · OPM change -5.9 pp 95% evidence | 14.3/25 ROCE 20.6% · OPM 14.8% 95% evidence | 10.8/20 P/E 25.5× · PEG — 15% evidence | 15.5/20 RS sector 15.7% · RS bench 38.2% · 1Y 42%9 of 9 weeks ahead 70% evidence |
| Exact sum: 5 + 14.3 + 10.8 + 15.5 = 45.6 · Decision use: Price leads the evidence: RS versus the benchmark is 38.2%, but earnings trajectory is weak. Wait for revenue and profit confirmation. | ||||||
| 10Beta Drugs LtdBETA | 45.0/100Mixed-negative evidence76% evidence | BREAKING OUT | 11.6/35 Revenue -11.3% · PAT -14.8% · OPM change 2 pp 95% evidence | 18.4/25 ROCE 19.2% · OPM 22% 76% evidence | 7.6/20 P/E 51.5× · PEG — 50% evidence | 7.4/20 RS sector -17.9% · RS bench 28% · 1Y 11.5%10 of 10 weeks ahead 70% evidence |
| Exact sum: 11.6 + 18.4 + 7.6 + 7.4 = 45 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 11Kopran LtdKOPRAN | 40.1/100Mixed-negative evidence81% evidence | TURNING | 14.5/35 Revenue 12% · PAT -28.4% · OPM change -0.2 pp 95% evidence | 9.6/25 ROCE 6.7% · OPM 10.3% 95% evidence | 7.1/20 P/E 45.5× · PEG — 50% evidence | 8.9/20 RS sector -17.6% · RS bench 46.7% · 1Y 32.9%10 of 11 weeks ahead 70% evidence |
| Exact sum: 14.5 + 9.6 + 7.1 + 8.9 = 40.1 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 12Orchid Pharma LtdORCHPHARMA | 36.9/100Mixed-negative evidence78% evidence | BREAKING OUT | 17.4/35 Revenue 14.1% · PAT -80% · OPM change 6.8 pp 74% evidence | 1.8/25 ROCE 1.7% · OPM 4.6% 100% evidence | 10.5/20 P/E 333× · PEG 1.77 65% evidence | 7.2/20 RS sector -19.8% · RS bench 30.5% · 1Y 40.7%11 of 11 weeks ahead 70% evidence |
| Exact sum: 17.4 + 1.8 + 10.5 + 7.2 = 36.9 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 13Aarti Pharmalabs LtdAARTIPHARM | 33.8/100Adverse evidence94% evidence | BREAKING OUT | 10.2/35 Revenue 1.2% · PAT -20.2% · OPM change 1 pp 100% evidence | 11.8/25 ROCE 10.7% · OPM 25% 100% evidence | 3.4/20 P/E 34.8× · PEG 5.52 100% evidence | 8.4/20 RS sector -10.7% · RS bench 13.2% · 1Y -6.3%5 of 10 weeks ahead 70% evidence |
| Exact sum: 10.2 + 11.8 + 3.4 + 8.4 = 33.8 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 14Themis Medicare LtdTHEMISMED | 28.5/100Adverse evidence72% evidence | LEADER | 6.1/35 Revenue -12.9% · PAT 100% · OPM change -50 pp 71% evidence | 2.5/25 ROCE 2.7% · OPM -60% 95% evidence | 8.5/20 P/E 939.2× · PEG — 15% evidence | 11.4/20 RS sector -8.6% · RS bench 25.2% · 1Y 27.9%9 of 12 weeks ahead 100% evidence |
| Exact sum: 6.1 + 2.5 + 8.5 + 11.4 = 28.5 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
Missing observations are not scored as bad. Their missing weight lowers confidence and pulls the final score toward neutral. PEG is not shown when the ratio cannot mean anything: the company must be making a profit, its price-to-earnings must be positive, and its three-year earnings growth must fall between 5% and 60%. Dividing a price multiple by a loss, or by growth measured off a tiny base, produces a number that looks precise and tells you nothing. Under relative strength, one mark per week shows the last 12 weeks: a mark is filled where the company led NIFTY 500 by 5% or more over the 13 weeks ending that week, which is the same test used everywhere on this site. Price stage places the company on the same six-step curve the sector itself is placed on — basing, turning, breaking out, leader, fading, asleep — read from how many weeks running it has led NIFTY 500 and whether that lead is widening or shrinking. It describes where the PRICE stands, not the earnings trajectory and not a recommendation, and it is left blank for a company whose weekly history is too short or too stale to read.
Frequently asked questions
What is Senores Pharmaceuticals Ltd's share price today?
Senores Pharmaceuticals Ltd trades at ₹1,467, +112.7% over the past year. The company is valued at ₹6,757 Cr. The stock sits at 94% of its 52-week range of ₹727–₹1,513, +32.6% versus its 200-day average. On the tape, the price is in a confirmed uptrend, 60 weeks in. — as of 11 September 2026.
What were Senores Pharmaceuticals Ltd's latest quarterly results?
Senores Pharmaceuticals Ltd reported revenue of ₹180 Cr and net profit of ₹30.0 Cr for the Jun 26 quarter. Revenue rose 30.4% and profit rose 42.9% year on year. Earnings per share were ₹6.67. The operating margin was 30.0%, 5.0 pp higher than a year earlier. — as of 11 September 2026.
What is Senores Pharmaceuticals Ltd's revenue?
Senores Pharmaceuticals Ltd reported revenue of ₹180 Cr in the Jun 26 quarter, +30.4% year on year. For the full FY26 fiscal year, revenue was ₹633 Cr (+59.0%). Over the last 4 years revenue compounded at 159.3% a year. — as of 11 September 2026.
What is Senores Pharmaceuticals Ltd's profit?
Senores Pharmaceuticals Ltd earned ₹30.0 Cr of net profit in the Jun 26 quarter, +42.9% year on year — the 7th straight quarter of growth. Full-year FY26 profit was ₹122 Cr. The operating margin ran 30.0% in the latest quarter. — as of 11 September 2026.
What is Senores Pharmaceuticals Ltd's market cap?
Senores Pharmaceuticals Ltd's market capitalisation is ₹6,757 Cr at a share price of ₹1,467. Market cap is the share price multiplied by shares outstanding, so it is restated whenever the price moves. — as of 11 September 2026.
What is Senores Pharmaceuticals Ltd's P/E ratio?
Senores Pharmaceuticals Ltd trades at a P/E of 53.5×, at the 86th percentile of its own 2-year range, against a long-run median of 44.2×. This is a comparison with the stock's own history, not a value call — as of 11 September 2026.
Does Senores Pharmaceuticals Ltd pay a dividend?
No — Senores Pharmaceuticals Ltd has recorded a dividend payout of 0% of profit in each of its last 5 reported fiscal years, so there is no payout history to quote. That is a reading of the filed annual statements, not an estimate. — as of 11 September 2026.
Is Senores Pharmaceuticals Ltd overvalued?
On its own history, Senores Pharmaceuticals Ltd looks expensive: its P/E of 53.5× sits at the 86th percentile of its 2-year range (long-run median 44.2×). That is a percentile read against the stock's own past, not a price opinion or a direction call. — as of 11 September 2026.
Is Senores Pharmaceuticals Ltd growing?
Yes — Senores Pharmaceuticals Ltd is growing: latest-quarter revenue +30.4% year on year, profit +42.9%, and the margin +5.0 pp at 30.0%. The 4-year compound rates are 159.3% (revenue) and 232.3% (profit). The earnings engine currently reads: improving — as of 11 September 2026.
How is Senores Pharmaceuticals Ltd performing?
Senores Pharmaceuticals Ltd is in a confirmed uptrend, 60 weeks in. Its latest quarter's revenue rose 30.4% and profit rose 42.9% year on year. Against the NIFTY 500 it has been ahead on a trailing-13-week view for 29 weeks. This describes what the data did, not a rating. — as of 11 September 2026.
Is Senores Pharmaceuticals Ltd in an uptrend?
Yes — the price is in a confirmed uptrend (week 60 of stage 2), trading +32.6% versus its 200-day average and at 94% of its 52-week range. Price stages cycle base → advance → top → decline, and the stage names where this stock sits in that cycle — as of 11 September 2026.
Is Senores Pharmaceuticals Ltd beating the market?
On recent form, yes — Senores Pharmaceuticals Ltd has been ahead of the NIFTY 500 on a trailing-13-week view for 29 straight weeks, the same metric the week-by-week ribbon on this page draws. Separately, on the cumulative view: over the last 1.7 years the stock moved +156% against the NIFTY 500's +3% — ahead of the index over the full window. — as of 11 September 2026.
Will Senores Pharmaceuticals Ltd's share price go up?
This page publishes no price forecast for Senores Pharmaceuticals Ltd. What it measures instead: the share price is ₹1,467, the price is in a confirmed uptrend 60 weeks in. Its P/E of 53.5× sits at the 86th percentile of its own 2-year range. — as of 11 September 2026.
Who owns Senores Pharmaceuticals Ltd?
Promoters hold 45.8% of Senores Pharmaceuticals Ltd, foreign institutions 6.6%, domestic institutions 9.8% and the public 37.8% (latest quarter). The biggest move on the register over the last two years: Foreign institutions added 2.4 points over 6 quarters. — as of 11 September 2026.
Does Senores Pharmaceuticals Ltd have too much debt?
It is moderate — Senores Pharmaceuticals Ltd's debt-to-equity is 0.37, and operating profit covers the interest bill 7×. FY26 borrowings were ₹342 Cr against equity of ₹934 Cr. Read the returns on this page with that leverage in mind — as of 11 September 2026.
What is Senores Pharmaceuticals Ltd's capex?
Senores Pharmaceuticals Ltd spent ₹769 Cr on capital expenditure over the last 3 fiscal years, a figure derived from the change in fixed assets plus depreciation. In FY26 alone that was ₹330 Cr, with ₹17.0 Cr in capital work-in-progress — capacity paid for but not yet earning. — as of 11 September 2026.
What is Senores Pharmaceuticals Ltd's cash flow?
Senores Pharmaceuticals Ltd generated ₹62.0 Cr of operating cash flow in FY26 and ₹−268 Cr of free cash flow after ₹330 Cr of capital spending. Reported profit that year was ₹122 Cr, so operating cash ran behind profit. Cash-flow resolution for India is annual. — as of 11 September 2026.
Is Senores Pharmaceuticals Ltd's profit real cash?
No — operating cash was negative over the last 3 fiscal years: Senores Pharmaceuticals Ltd consumed cash while reporting profit. In FY26, operating cash was ₹62.0 Cr against reported profit of ₹122 Cr. Cash-flow resolution is annual — as of 11 September 2026.
Where is Senores Pharmaceuticals Ltd in its business cycle?
Senores Pharmaceuticals Ltd's FY26 operating margin was 27.0%, against a 5-year band of 14.0%–36.0%: mid-band by its own history — neither the peak that precedes mean-reversion nor the trough that precedes recovery. The latest quarter ran 30.0%. Profitability versus a company's own long band is the cleanest cycle clock this page holds — as of 11 September 2026.
What growth does Senores Pharmaceuticals Ltd's price assume?
At its price on 26 August 2026, Senores Pharmaceuticals Ltd was priced for profit growth of about 28.0% a year. Profit itself has compounded 232.3% a year over the past 4 years. The figure reads the multiple backwards: the growth a buyer at that price was already paying for. — as of 11 September 2026.
What could break the Senores Pharmaceuticals Ltd story?
The sharpest disagreement: profits are rising, but only −5% of the last 3 years' profit arrived as operating cash — the gap between the P&L and the bank account is the thing to watch. Mechanically, two Friday closes in a row below the 200-day average would end the price trend — that is the exit rule this page tracks — as of 11 September 2026.
Is Senores Pharmaceuticals Ltd a stock worth studying right now?
This is not investment advice. The machine read: Senores Pharmaceuticals Ltd is strength at full price. The numbers are improving — and a P/E at the 86th percentile of its own range says the market knows. The sharpest open question: whether the cash starts following the profit. Every number on this page is drawn deterministically from the raw series, with no forecasts and no price opinions — as of 11 September 2026.
Not SEBI Registered !! Not Investment advice !!